# Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

> **NCT04262336** · PHASE1 · COMPLETED · sponsor: **Decibel Therapeutics** · enrollment: 22 (actual)

## Conditions studied

- Ototoxicity

## Interventions

- **DRUG:** DB-020
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04262336
- **Lead sponsor:** Decibel Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-21
- **Primary completion:** 2022-07-30
- **Final completion:** 2023-05-23
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04262336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04262336, "Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04262336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*